Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-PRIDE-HD extension study of pridopidine in Huntington's disease
2015-000904-24Phase 2Terminated
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pridopidine in Huntington disease (HD), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Safety and tolerability of pridopidine. Started Aug 2015; status: terminated.
02
Drugs
pridopidine
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on 2015-000904-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000904-24.